Identification of a novel synergistic induction of cell death by Smac mimetic and HDAC inhibitors in acute myeloid leukemia cells.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Science Ireland Country of Publication: Ireland NLM ID: 7600053 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7980 (Electronic) Linking ISSN: 03043835 NLM ISO Abbreviation: Cancer Lett Subsets: MEDLINE
    • Publication Information:
      Publication: Limerick : Elsevier Science Ireland
      Original Publication: Amsterdam, Elsevier/North-Holland.
    • Subject Terms:
      Apoptosis/*drug effects ; Histone Deacetylase Inhibitors/*pharmacology ; Leukemia, Myeloid, Acute/*drug therapy ; Oligopeptides/*pharmacology; Amino Acid Chloromethyl Ketones/pharmacology ; Caspases/physiology ; Cell Line, Tumor ; Drug Synergism ; Humans ; Leukemia, Myeloid, Acute/pathology ; Signal Transduction ; Tumor Necrosis Factor-alpha/physiology
    • Abstract:
      Inhibitor of Apoptosis (IAP) proteins are expressed at high levels in acute myeloid leukemia (AML) and contribute to resistance to programmed cell death. Here, we report that inhibition of IAP proteins by the small-molecule Smac mimetic BV6 acts together with histone deacetylase (HDAC) inhibitors (HDACIs) such as MS275 or SAHA to trigger cell death in AML cell lines in a synergistic manner, as underscored by calculation of combination index (CI). Also, BV6 and HDACIs cooperate to trigger DNA fragmentation, a marker of apoptotic cell death, and to suppress long-term clonogenic survival of AML cells. In contrast, equimolar concentrations of BV6 and MS275 or SAHA do not synergize to elicit cell death in normal peripheral blood lymphocytes (PBLs), emphasizing some tumor cell selectivity of this combination treatment. Addition of the tumor necrosis factor (TNF)α-blocking antibody Enbrel significantly reduces BV6/MS275-induced cell death in the majority of AML cell lines, indicating that autocrine/paracrine TNFα signaling contributes to cell death. Remarkably, the broad-range caspase inhibitor N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (zVAD.fmk) fails to rescue MV4-11, Molm13 and OCI-AML3 cells and even enhances BV6/MS275-mediated cell death, whereas zVAD.fmk reduces BV6/MS275-induced cell death in NB4 cells. Annexin-V/propidium iodide (PI) double staining reveals that BV6/MS275 cotreatment predominately increases the percentage of double-positive cells. Of note, the Receptor-Interacting Protein (RIP)1 inhibitor necrostatin-1 (Nec-1) or the Mixed Lineage Kinase Domain-Like protein (MLKL) inhibitor necrosulfonamide (NSA) significantly reduce BV6/MS275-induced cell death in the presence of zVAD.fmk, suggesting that BV6/MS275 cotreatment triggers necroptosis when caspases are inhibited. Thus, BV6 acts in concert with HDACIs to induce cell death in AML cells and can bypass apoptosis resistance, at least in several AML cell lines, by engaging necroptosis as an alternative route of regulated cell death. The identification of a novel synergism of BV6 and HDACIs has important implications for the development of new treatment strategies for AML.
      (Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.)
    • Contributed Indexing:
      Keywords: Apoptosis; Leukemia; Necroptosis; Smac
    • Accession Number:
      0 (Amino Acid Chloromethyl Ketones)
      0 (BV6 peptide)
      0 (Histone Deacetylase Inhibitors)
      0 (Oligopeptides)
      0 (Tumor Necrosis Factor-alpha)
      0 (benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone)
      EC 3.4.22.- (Caspases)
    • Publication Date:
      Date Created: 20150602 Date Completed: 20150930 Latest Revision: 20220310
    • Publication Date:
      20250114
    • Accession Number:
      10.1016/j.canlet.2015.05.020
    • Accession Number:
      26028172